Jeffrey Tarrand

This inventor holds 12 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 3 EPO patents. Top assignees: The University of Texas System, Platform Brightworks Two, Ltd., Other. Active years: 2002-2021.

USPTO Granted Patents = 12 (Patent Applications = 1)

% Patents Active = 83.3

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 48(Granted Patents)

Company Filing History:

6 out of 5,630

The University of Texas System

patents

5 out of 5

Platform Brightworks Two, Ltd.

patents

1 out of 834,411

Other

patents

Years Active: 2002-2021

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11045466 - Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same (2021-06-29),

2. 10897891 - Compositions and methods for prolonged cell storage (2021-01-26),

3. 10646574 - Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same (2020-05-12),

4. 10548890 - Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same (2020-02-04),

5. 10307418 - Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds (2019-06-04),

6. 10028949 - Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same (2018-07-24),

7. 9724345 - Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same (2017-08-08),

8. 9364433 - Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same (2016-06-14),

9. 8512724 - Antiseptic compositions (2013-08-20),

10. 7807179 - Modified reoviral therapy (2010-10-05),

11. 7223388 - Modified reoviral therapy (2007-05-29),

12. 6444872 - Large animal model of invasive pulmonary aspergillosis in an immunocompromised host (2002-09-03),

Title: Innovations and Contributions of Jeffrey Tarrand

Introduction

Jeffrey Tarrand is a notable inventor based in Houston, TX, with a significant portfolio of 12 patents. His work primarily focuses on pharmaceutical formulations and methods that enhance the efficacy and stability of lipophilic agents.

Latest Patents

Among his latest patents is a groundbreaking invention related to parenteral formulations of lipophilic pharmaceutical agents. This invention provides compositions that improve solubility and stability, utilizing a non-aqueous composition that includes a lipophilic pharmaceutical agent and an amphiphilic polymeric solvent, such as PEG400. This formulation is designed to be essentially free of organic solvents and non-solubilized particles, making it suitable for parenteral administration to humans. Another significant patent involves methods and compositions for prolonged cell storage, particularly for preserving platelets or other cells. This storage media may include low molecular weight polyethylene glycol, allowing for extended storage and refrigeration of the cells.

Career Highlights

Jeffrey has made substantial contributions to the field through his work with the University of Texas System and Platform Brightworks Two, Ltd. His innovative approaches have led to advancements in pharmaceutical applications, particularly in the treatment of diseases sensitive to lipophilic agents.

Collaborations

Throughout his career, Jeffrey has collaborated with esteemed colleagues, including Borje S Andersson and Benigno C Valdez. These partnerships have further enriched his research and development efforts.

Conclusion

Jeffrey Tarrand's contributions to pharmaceutical innovations demonstrate his commitment to improving medical treatments through advanced formulations. His patents reflect a deep understanding of the complexities involved in drug delivery and cell preservation.